Skip to main content
Erschienen in: Reactions Weekly 1/2013

01.07.2013 | News item

Olmesartan label to warn of sprue-like side effects

Erschienen in: Reactions Weekly | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Excerpt

US labels for the antihypertensive olmesartan medoxomil [Benicar, Benicar HCT, Azor, Tribenzor, and generics] are to be updated to warn of the risk of sprue-like enteropathy. …
Fußnoten
1
see Reactions 1432 p39; 803081129
 
Literatur
Zurück zum Zitat FDA. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. Internet Document : [4 pages], 3 Jul 2013 FDA. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. Internet Document : [4 pages], 3 Jul 2013
Metadaten
Titel
Olmesartan label to warn of sprue-like side effects
Publikationsdatum
01.07.2013
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2013
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-013-4524-5

Weitere Artikel der Ausgabe 1/2013

Reactions Weekly 1/2013 Zur Ausgabe

Case report

Rifampicin

Case report

Vemurafenib

Case report

Clozapine

Case report

Pazopanib